Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 8INDUSTRY 4OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 208Carcinoma, Ovarian Epithelial 133Fallopian Tube Neoplasms 117Uterine Cervical Neoplasms 103Breast Neoplasms 76Endometrial Neoplasms 73Pancreatic Neoplasms 33Neoplasms 31Colonic Neoplasms 28Stomach Neoplasms 27Carcinoma, Non-Small-Cell Lung 27Prostatic Neoplasms 26Testicular Neoplasms 24Sarcoma 23Lung Neoplasms 23Melanoma 22Carcinoma, Renal Cell 22Rectal Neoplasms 21Colorectal Neoplasms 20Vaginal Neoplasms 18Uterine Cervical Dysplasia 18Carcinoma, Hepatocellular 18Neoplasm Metastasis 17Anus Neoplasms 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Esophageal Neoplasms 16Brenner Tumor 16Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Vulvar Neoplasms 14

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced Ovarian Cancer × Gynecologic × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡